P16 Staining as Prognostic Biomarker in Serous Papillary Endometrial Cancer

This study has been completed.
Information provided by:
Rambam Health Care Campus
ClinicalTrials.gov Identifier:
First received: December 15, 2010
Last updated: December 26, 2010
Last verified: November 2010

P16 is a tumor suppressor protein implicated in serous papillary endometrial carcinoma. Evidence from previous trials indicates that it may be used as a diagnostic biomarker distinguishing this disease from endometrioid endometrial cancer. Additional evidence points to its prognostic value.

The current study will evaluate p16 both as a diagnostic tool for serous papillary endometrial cancer and as a prognostic biomarker.

following anonymization, histology blocks will be microtomed and stained for P16 and P53 proteins.

Blocks from endometrioid endometrial cancer will be used as a control group.

Condition Intervention
Serous Papillary Endometrial Cancer
Other: no intervention

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Expression of the P16 Protein in Serous Papillary Endometrial Cancer, and Its Clinical and Prognostic Significance

Resource links provided by NLM:

Further study details as provided by Rambam Health Care Campus:

Primary Outcome Measures:
  • Overall survival [ Time Frame: last followup (2-10 years) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • progression free survival [ Time Frame: Current follow up (2-10 years) ] [ Designated as safety issue: No ]
  • correlation of P16 stain with histological diagnosis [ Time Frame: at last follow up (2-10 years) ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Existing paraffin pathology blocks in hospital's library were used. Remainder of material was returned to the library.

No identifying features were retained or attached to specimens.

Enrollment: 62
Study Start Date: July 2010
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Serous papillary endometrial ca patients
30 patients diagnosed with SP endometrial ca
Other: no intervention
Endometrioid endometrial ca
32 patients diagnosed with Endometrioid endometrial ca
Other: no intervention


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
women diagnosed with endometrial cancer, having undergone surgery and having received chemotherapy in our institution.

Inclusion Criteria:

  • diagnosis of endometrial cancer
  • histology block exists in hospital's library

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01267357

Rambam Medical Center
Haifa, Israel
Sponsors and Collaborators
Rambam Health Care Campus
  More Information

Responsible Party: Dr. Itamar Netzer, Rambam Medical Center
ClinicalTrials.gov Identifier: NCT01267357     History of Changes
Other Study ID Numbers: 230CTIL 
Study First Received: December 15, 2010
Last Updated: December 26, 2010
Health Authority: Israel: Ministry of Health

Keywords provided by Rambam Health Care Campus:
Serous Papillary Endometrial Cancer
Endometrioid endometrial cancer

Additional relevant MeSH terms:
Endometrial Neoplasms
Genital Diseases, Female
Genital Neoplasms, Female
Neoplasms by Site
Urogenital Neoplasms
Uterine Diseases
Uterine Neoplasms

ClinicalTrials.gov processed this record on May 26, 2016